Stacchiotti, S, Yonemori, K, Beato, CM, Campos, FAB, Conley, AP, Debruyne, C, Endo, M, Hiraga, H, Kichenadasse, G, Laptewicz, M, Lleida, RT, Morais, ANR, Yoshihiro, N, Pereira, C, Salawu, AT, Takenaka, S, Tanaka, K, Tinoco, G, Vianna, KM, Bovée, JVMG. Isocitrate dehydrogenase 1 (IDH1) mutation testing in the phase III study of ivosidenib vs placebo in IDH1-mutant conventional chondrosarcoma (CHONQUER). ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3355. PMID:. IF:65.400(Q1/1D).

Molasiotis, A, Jordan, K, Karthaus, M, Dranitsaris, G, Roeland, EJ, Schwartzberg, LS, Bonizzoni, E, Vazquez, EB, Buchler, T, Cheng, Y, Christoph, DCC, Alfonso, PG, Lu, X, Majem, M, Mavroudis, D, Syrigos, K, Tomlins, E, Zhou, Z, Zimovjanova, M, Aapro, MS. Personalizing antiemetic prophylaxis for patients at high emetic risk: Results from the MyRisk Trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3413. PMID:. IF:65.400(Q1/1D).

Bernabé, R, De Castro, J, Collado, R, Escudero, V, Gutiérrez, F, Arranz, S, Gordo, R, Arroyo, I, Majem, M. Economic Burden of Disease Management and Recurrences After Complete Resection of Early-Stage ALK plus Non-Small Cell Lung Cancer (NSCLC) in Spain. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Johnson, ML, Arriola, E, Kato, T, Girard, N, Gadgeel, S, Tarruella, MM, Newsom-Davis, T, Polaczek, M, Chen, X, Stefaniak, K, Lowery, C, Angra, N, Doherty, G, Ahn, MJ. Phase 3 eVOLVE-Lung02 Trial of Volrustomig plus Chemotherapy (CT) vs Pembrolizumab plus CT in Metastatic NSCLC With PD-L1 TC <50%. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Lopez, JS, Besora, CP, Verge, MM, Joaquin, AB, Recio, SM, Pastor, M, Fierro, JP, Martinez-Esparza, EH, Martinez-Momblan, MA, Majem, M. Non-Pharmacological Dermatologic Care for the Prevention and Management of Immune-Related Skin Toxicities in Patients With Lung Cancer. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Nadal, E, Cantero, A, Paz-Ares, L, Ortega, AL, Barba, A, Iranzo, P, Domine, M, Garcia, J, Blasco, A, Campelo, RG, Rodriguez-Abreu, D, Castro, RL, Vidal, OJ, Tena, I, Diz, P, Provencio, M, Simo, M, Vilariño, N, Navarro,, Bruna, J. NIVIPI-Brain: Phase 2 Study of Nivolumab plus Ipilimumab Combined With Chemotherapy in NSCLC With Synchronous Brain Metastases. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

Torresan, S, Torres, CSD, Caramella, C, Ambrosini, P, Gomez-Randulfe, I, Monaca, F, Ribera, A, Goudsmit, A, Michelini, A, Segui, V, Insa, A, Martorell, PM, Romero-Sola, G, Caro-Consuegra, R, Mirallas, O, Priano, I, Valdivia, A, Masfarré, L, Iranzo, P, Martinez-Marti, A, Cedres, S, Catot, S, Sequeira, T, Callejo, A, Bearz, A, Barba, A, Antoñanzas, M, Sais, E, Baena, J, Brandao, M, Mosteiro, M, Vilariño, N, Gambardella, V, Moran, T, Occhipinti, M, Califano, R, Pardo, N, Felip, E, Rocha, P. Histological Transformation as Resistance Mechanism in NSCLC: A Multicenter Study Exploring Clinico-Pathological and Molecular Features. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).

De Castro, J, Bernabé, R, Escudero, V, Gutiérrez, F, Majem, M, Gordo, R, Arroyo, I, Arranz, S, Collado, R. Benefits of Adjuvant Alectinib in ALK plus Early-Stage Non-Small Cell Lung Cancer, Recurrences Avoided and Savings for the Spanish Health System. Journal of Thoracic Oncology. 2025; 20(10)DOI:. PMID:. IF:20.800(Q1/1D).